Group B streptococcus is one of the biggest killers of newborns in both wealthy and disadvantaged countries alike; now we are closer to a vaccine that could save thousands of lives every year.
MinervaX reveals completion of vaccine trial enrolment pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has.
/PRNewswire/ MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first.